oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes trial New Science Suggests Improves CV Beyond Weight Loss Semaglutide cardiovascular outcomes – Cardiovascular Outcomes Associated with Semaglutide

Here is a quick snapshot of what researchers and observers are currently seeing in June 2026: All figures reflect research and investigational contexts

It facilitates your bodys use of energy, which promotes healthy metabolism and can aid those dealing with diet or exercise resistant body fat

Joint Bone Spine

Hyett B, Martinez FJ, Gill BM, et al

Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively